This weeks NEJM has a quite striking phase III trial comparing a gefitinib to a carbo-taxol in a carefully selected cohort: non or light smokers from east asia with adenocarcinoma of the lung. This subset has been previously described as having an excellent response to treatment, but the very positive results of this trial prove a very significant benefit to disease free survival, and also demonstrate that the benefit in this subpopulation is related to EGFR mutation status.
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma
Thursday, August 20, 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment